ProImmune Ltd, a leader in epitope discovery, immunogenicity, and immune monitoring products and services, launched CFSE T cell proliferation assays for immunogenicity risk assessment. The assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.
 
Combined with ProImmune’s unique cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.

Unlike traditional assays, which are based on radioactive thymidine incorporation, ProImmune’s new assays utilise powerful flow cytometry methods, enabling accurate determination of the percentage of proliferating CD4-positive cells and detailed phenotyping of T cell responses with significantly improved overall sensitivity.